BALPHARMA.BOBALPHARMA.BOBSE
Loading
Net Income Growth Under PressureDecelerating
Percentile Rank69
3Y CAGR-28.0%
Year-over-Year Change
Year-over-year net income growth rate
3Y CAGR
-28.0%/yr
vs +155.8%/yr prior
Acceleration
-183.7pp
Decelerating
Percentile
P69
Within normal range
vs 3Y Ago
0.4x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 150.87% |
| Q3 2025 | 253.69% |
| Q2 2025 | -96.31% |
| Q1 2025 | 1029.22% |
| Q4 2024 | -53.82% |
| Q3 2024 | 302.12% |
| Q2 2024 | -95.27% |
| Q1 2024 | 515.74% |
| Q4 2023 | -6.01% |
| Q3 2023 | -20.88% |
| Q2 2023 | -25.32% |
| Q1 2023 | 178.38% |
| Q4 2022 | 403.86% |
| Q3 2022 | -59.89% |
| Q2 2022 | -85.56% |
| Q1 2022 | 208.16% |
| Q4 2021 | -53.63% |
| Q3 2021 | -16.37% |
| Q2 2021 | -53.91% |
| Q1 2021 | 1028.80% |
| Q4 2020 | -25.31% |
| Q3 2020 | 0.43% |
| Q2 2020 | 110.40% |
| Q1 2020 | -9.60% |
| Q4 2019 | -86.29% |
| Q3 2019 | 19.09% |
| Q2 2019 | -183.53% |
| Q1 2019 | 85.86% |
| Q4 2018 | 309.91% |
| Q3 2018 | -147.64% |
| Q2 2018 | 562.48% |
| Q1 2018 | -172.61% |
| Q4 2017 | -25.25% |
| Q3 2017 | 198.66% |
| Q2 2017 | 27.14% |
| Q1 2017 | -244.42% |
| Q4 2016 | -65.27% |
| Q3 2016 | 246.16% |
| Q2 2016 | 119.32% |
| Q1 2016 | -238.41% |